Published in Drug Law Weekly, September 18th, 2007
The Court agreed with Merck that the case was not an appropriate one to be handled as a class action because the claims of the insurance companies and HMOs involved different facts.
"The Supreme Court recognized that a class action was improper because each insurance company and HMO considered different types of information in deciding whether to reimburse patients for VIOXX, and they all...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.